stockrowIndivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
Follow SUPN
Alert me
Indivior Pharmaceuticals Inc. (SUPN) Total debt
Indivior Pharmaceuticals Inc.'s total debt at the end of fiscal 2025 was $319.0M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $488.0M. Over the past ten years it has ranged from $234.0M (fiscal 2020) to $605.0M (fiscal 2015); the current reading is higher than 64% of that period. Indivior Pharmaceuticals Inc. ranks 21st of 84 Drug Manufacturers Specialty & Generic companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $319.0M | (4.20%) |
| FY2024 | $333.0M | 38.75% |
| FY2023 | $240.0M | 0.00% |
| FY2022 | $240.0M | (0.83%) |
| FY2021 | $242.0M | 3.42% |
| FY2020 | $234.0M | (1.27%) |
| FY2019 | $237.0M | (1.66%) |
| FY2018 | $241.0M | (50.00%) |
| FY2017 | $482.0M | (9.91%) |
| FY2016 | $535.0M | (11.57%) |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $488.0M | 0.21% |
| Jun 2026 | $487.0M | 0.21% |
| Mar 2026 | $486.0M | 52.35% |
| Dec 2025 | $319.0M | (0.93%) |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $3.2B |
| ALKS Alkermes plc compare | $1.5B |
| HIMS Hims & Hers Health, Inc. compare | $1.4B |
| RDY Dr. Reddy's Laboratories Ltd compare | $753.0M |
| LNTH Lantheus Holdings, Inc. compare | $571.7M |
| SUPN Indivior Pharmaceuticals Inc. | $488.0M |
| LQDA Liquidia Corporation compare | $176.1M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $13.0M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | $1.4M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on SUPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement